
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : ADCX-020
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Bpifrance
Deal Size : $122.0 million
Deal Type : Series A Financing
Adcytherix Raises EUR 105M to Accelerate Antibody-Drug Conjugate Pipeline
Details : The Series A financing for ADCX-020, an unconjugated antibody targeting undisclosed cancer, aims to advance cancer therapeutics.
Product Name : ADCX-020
Product Type : Antibody, Unconjugated
Upfront Cash : Undisclosed
October 16, 2025
Lead Product(s) : ADCX-020
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Bpifrance
Deal Size : $122.0 million
Deal Type : Series A Financing

Adcytherix Launches with €30 Million in Seed Funding for Antibody Drug Conjugates
Details : The financing aims to fund Adcytherix to develop next-generation antibody-drug conjugates for the treatment of patients suffering from high unmet-need diseases such as neoplasms.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
June 11, 2024
